For the millions living with cutaneous lupus erythematosus—a disfiguring autoimmune condition causing scarring skin lesions and profound quality-of-life loss—standard treatments frequently fail. This systematic review consolidates the strongest available randomized evidence on whether next-generation biologics and small molecules can reliably move the needle when conventional options fall short.
Drawing from eight randomized controlled trials identified across MEDLINE, Embase, and LILACS, the review focused on agents targeting two central immune axes: type I interferon (IFN-I) and tumor necrosis factor-alpha (TNF-α). The IFN-I inhibitor anifrolumab emerged as the most consistently supported agent, achieving CLASI-50 responses—a validated measure of 50% improvement in active skin disease—in 49% of treated patients versus 25% on placebo in the pivotal TULIP-2 trial, with even stronger signals (63% vs. 31%) in the earlier MUSE study. Sifalimumab, another IFN-I antagonist, reached CLASI-50 rates as high as 73%. Newer mechanisms also showed promise: deucravacitinib, a TYK2 kinase inhibitor modulating IFN and cytokine signaling, and BIIB059, targeting the plasmacytoid dendritic cell receptor BDCA2, both demonstrated meaningful cutaneous improvement. Conversely, RSLV-132 and epratuzumab showed no meaningful efficacy. IFN-I pathway inhibition carried a consistent safety signal: elevated rates of viral infections, particularly herpes reactivation.
This review arrives at a critical inflection point. Anifrolumab received FDA approval for systemic lupus in 2021, and dermatologists are increasingly encountering it in practice. However, most trials enrolled patients with concurrent systemic disease, leaving pure cutaneous lupus as an underexplored subgroup. The narrative synthesis—necessitated by clinical heterogeneity across trials—limits pooled quantitative conclusions, and head-to-head comparisons between agents do not yet exist. The absence of TNF-α blockade efficacy data is notable, echoing prior paradoxical observations that TNF inhibitors can actually induce lupus-like reactions in some patients. For now, IFN-I inhibition represents the most evidence-supported targeted approach, though the infection risk profile warrants careful patient selection.